Диссертация (1141206), страница 26
Текст из файла (страница 26)
Physiol. Regul. Integr. Comp. Physiol. — 2005. — Vol.288(1). — P.46–53.213. Rosen J.B., Schulkin J. From normal fear to pathological anxiety //Psychol. Rev. — 1998. — Vol. 105. — P.325–350.214. Rossi A.M., Vilska S., Heionen P.K. Outcome of pregnancies inwomen with treated and untreated hyperprolactinemia // Eur. J .Obstetr. Gynecol.Reprod. Biol. — 1995. — Vol. 63, № 3. — P.143–146.215. Saharkhiz N., Akbari Sene A., Salehpour S. et al. Treatment results ofhigh dose cabergoline as an adjuvant therapy in six patients with established severeovarian hyper stimulation syndrome // Iran J. Reprod. Med.
— 2014. — Vol.12(10). — P.713–716.216. Sandman C.A., Glynn L., Schetter C.D. et al. Elevated maternalcortisol early in pregnancy predicts third trimester levels of placental corticotropinreleasing hormone (CRH): priming the placental clock // Peptides.
— 2006. —Vol. 27. — P.1457–1163.150217. Sandman C.A., Davis E.P. Gestational stress influences cognition andbehavior // Future Neurol. — 2010. — Vol. 5. — P.675–690.218. Sandman C.A., Davis E.P., Buss C., Glynn L.M. Prenatalprogramming of human neurological function // Int.
J. Pept. — 2011. — Vol.83.— P.7596.219. Sandman C.A., Davis E.P. Health risk is associated with gestationalexposure to stress hormones // Expert Review of Endocrinology and Metabolism.— 2012. — Vol.7 (4).– P.445–459.220. Sata F., Yamada H., Yamada A. et al. A polymorphism in the CYP17gene relates to the risk of recurrent pregrancy loss // Mol. Hum Reprod.
— 2003.— Vol.9 (11). — P.725–728.221. Schaffer L., Luzi F., Burkhardt T. et al. Antenatal betamethasoneadministration alters stress physiology in healthy neonates // Obstet. Gynecol. —2009. — Vol. 113.– P.1082–1088.222. Scialli A.R. Developmental effects of progesterone and its derivatives// Reprod.
Toxicol. — 1988. — Vol. 2. — P.3–11.223. Scott S. Parenting quality and children's mental health: biologicalmechanisms and psychological interventions // Curr. Opin. Psychiatry. — 2012.— Vol.25 (4). — P.301–306.224. Seckl J.R. Prenatal glucocorticoids and long–term programming //Eur. J. Endocrinol. — 2004. — Vol.151 (3). — P.49–62.225. Shirkey H.C. Human experiences related to adverse drug reactions tothe fetus or neonate from some maternally administered drugs // Adv.
Exp. Med.Biol. — 1972. — Vol.27. — P.17–30.226. Showell M.G., Brown J., Clarke J. et al. Antioxidants for femalesubfertility // Cochrane Database Syst. Rev. — 2013. — Vol. 8. — CD007807.227. Silver R.I. Endocrine abnormalities in boys with hypospadias // Adv.Exp. Med. Biol. — 2004. — Vol.545. — P.45–72.151228. Sloboda D.M., Moss T.J., Gurrin L.C. et al. The effect of prenatalbetamethasone administration on postnatal ovine hypothalamic–pituitary–adrenalfunction // J. Endocrinol. — 2002.
— Vol.172. — P.71–81.229. Sloboda D.M., Moss T.J., Li S. et al. Prenatal betamethasone exposureresults in pituitary–adrenal hyporesponsiveness in adult sheep // Am. J. Physiol.Endocrinol. Metab. — 2007. — Vol. 292. — P.61–70.230. Smith R., Smith J.I., Shen X. et al. Patterns of plasma corticotropin–releasing hormone, progesterone, estradiol, and estriol change and the onset ofhuman labor // J.
Clin. Endocr. Metab. — 2009. — Vol. 94. — P.2066–2074.231. Smitz J., Devroey P., Faguer B. et al. A randomized prospective studycomparing supplementation of the luteal phase and early pregnancy by naturalprogesterone administered by intramuscular or vaginal route // Rev. Fr. Gynecol.Obstet. — 1992. — Vol.87. — P. 507–516.232. Spinillo A., Viazzo F, Colleoni R.
et al. Two–year infantneurodevelopment outcome after single or multiple antenatal courses ofcorticosteroids to prevent complication of prematurity // Am. J. Obstet. Gynecol.— 2004. — Vol.191 (1). — P. 217–224.233. Stojanoski M.M., Nesterovic N., Negic N.
et al. The pituitary–adrenalaxis of fetal rats after maternal dexamethasone treatment // Anat. Embryol. (Berl).— 2006. — Vol. 211 (1). — P. 61–69.234. Stoll C., Alembik Y., Roth M., Dott B. Genetic and environmentalfactors in hypospadias // J. Med. Genet. — 1990. — Vol. 27. — P.559–563.235. Sugiura–Ogasawara M., Ozaki Y., Sato T. et al. Poor prognosis ofrecurrent aborters with either maternal or paternal reciprocal translocations //Fertil.
Steril. — 2004. –Vol.81 (2). — P.367–373.236. Swanson J. Compliance with stimulants for attention–deficit/hyperactivity disorder. Issues and approaches for improvement // CNS Drugs. —2003. — Vol. 17. — P. 117–131.237. Tegethoff M., Pryce C., Meinlschmidt G. Effects of intrauterineexposure to synthetic glucocorticoids on fetal, newborn, and infant hypothalamic–152pituitary–adrenal axis function in humans: a systematic review // Endocr. Rev.
—2009. — Vol.30. — P.753–789.238. The Practice Committee of the American Society for ReproductiveMedicine // Fertil. Steril. — 2012. — Vol.98. — P.1103 — 1111.239. Thorin–Savoure A., Kuhn J.M. Hyperandrogenism and pregnancy //Ann. Endocrinol. (Paris). — 2002. — Vol.63 (5). — P.443–451.240. Troisi R., Hatch E.E., Titus–Ernstoff L., et al. Cancer risk in womenprenatally exposed to diethylstilbestrol // Int.
J Cancer. — 2007. — Vol.121. —P.356–360.241. Ulfig N., Setzer M., Bohl J. Ontogeny of the human amygdale // Ann.NY Acad. Sci. — 2003. — Vol.985. — P.22–33.242. Van den Boogaard E., Hermens E.P., Kremer J.A. et al. Reccurentmiscarriage: guidelines could be improved // Hum. Reprod. — 2014. — Vol.26. —№6. — P.1345.243. Viniker D.A. Mechanism action of Duphaston // Human. Reprod. —1996. — Vol. 11, №7. — P.
1435–1477.244. Wagner C.K. Progesterone receptors and neural development: a gapbetween bench and bedside? // Endocrinology. — 2008. — Vol. 149, №6. — P.2743–2752.245. Wapner R., Sorokin Y., Mele L. et al. Long–term outcomes afterrepeat doses of antenatal corticosteroids // New Engl. J. Med.— 2007. —Vol.357. — P.1190–1198.246. Wapner R., Jobe A.H. Controversy: antenatal steroids // Clin.Perinatol. — 2011. –Vol. 38. — P.529–545.247.
Weinberg J., Sliwowska J.H., Lan N., Hellemans K.G. Prenatalalcohol exposure: foetal programming, the hypothalamic–pituitary–adrenal axisand sex differences in outcome // J. Neuroendocrinol. — 2008. — Vol.20. —P.470–488.248. Weinstock M. The long–term behavioural consequences of prenatalstress // Neurosci Biobehav Rev. — 2008. — Vol. 32. — P.1073–1086.153249. Witter F.R., Zimmerman A.W., Reichmann J.P., Connors S.L.
In uterobeta 2 adrenergic agonist exposure and adverse neurophysiologic and behavioraloutcomes // Am. J. Obstet. Gynecol. — 2009. — Vol. 201. — P.553–559.250. Wright V.C., Schieve L., Reynolds M.A. et al. Assisted reproductivetechnology surveillance — United States, 2001 // MMWR Surveil. Summ. —2004. — Vol.53 (1). — P.20.251. Xia P., Younglai E.V. Relationship between steroid concentrations inovarian follicular fluid and oocyte morphology in patients undergoingintracytoplasmic sperm injection (ICSI) treatment // J. Reprod.
Fertil. — 2000. —Vol. 118, № 2. — P.229–233.252. Zerrate M.C., Pletnikov M., Connors S.L. et al. Neuroinflammationand behavioral abnormalities after neonatal terbutaline treatment in rats:implications for autism // J. Pharmacol. Exp. Ther.
— 2007. — Vol.322. — P.16–22.253. Zhang J., Yao G.Y., Fang B.H. Survey on physical development ofchildren under 7–year–old in Shanghai in 2005 // J. Clin. Pediatr. — 2007. — Vol.25. — P.684–688.254. Zhang L., Ye W., Yu W. et al. Physical and mental development ofchildren after levonorgestrel emergency contraception exposure: a follow–upprospective cohort study1 // Biol. Reprod. — 2014. — Vol.91(1). — P.27.255. Zhang L., Chen J.L., Wang Y.S. et al. Pregnancy outcome afterlevonogestrel–only emergency contraception failure: a prospective cohort study //Human Reproduction. — 2009. — Vol.
1. — P.1–7..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
